SEC Filing Analysis: Alpha Tau Medical Ltd.

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer of Alpha Tau Medical has filed an intention to sell a small number of shares under a pre-arranged 10b5-1 trading plan.
• Market Impact: The transaction is negligible in size relative to the company's market capitalization and is not expected to have any market impact.

Company Information

Field	Value
Company	Alpha Tau Medical Ltd.
Ticker Symbol	null
CIK	0001871321
Industry	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Insider Information

Field	Value
Name	Gat Amnon
CIK	0001968258
Title/Position	null
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-03
Transaction Code	null
Security Type	Ordinary
Shares Involved	16,000
Price Per Share	$4.165
Total Value	$66,640
Shares Owned After	null
Ownership Type	null

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$66,640
% of Market Cap	0.019%
Shares Transacted	16,000
% of Shares Outstanding	0.019%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $350 million, a transaction valued at approximately $67k is considered routine and immaterial.
• Transaction Significance: The sale represents a tiny fraction of both the market capitalization (0.019%) and the total shares outstanding (0.019%), falling well below the thresholds for moderate or high significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction's low value and its execution under a pre-established 10b5-1 plan remove any new informational content. Such sales are typically for liquidity or diversification and are not indicative of the insider's current sentiment.

Volume & Sentiment

• Expected Volume Impact: None. The number of shares is too small to affect trading volume noticeably.
• Sentiment Indicator: Neutral. The market generally disregards small, planned sales by insiders.

Additional Context

Special Circumstances

• The filing explicitly states the proposed sale is under a 10b5-1 plan adopted on March 24, 2025. This indicates the decision to sell was made months in advance, insulating it from being based on recent non-public information.
• The filing also notes a prior sale of 16,000 shares on October 1, 2025, suggesting a regular, programmatic selling schedule.